Wjahat A. Waraich

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Although lenalidomide and pomalidomide are well-established treatment options in patients with multiple myeloma, their immune-modulating effects are not fully understood. While CD8+CD28- regulatory T-cells in patients with hematologic disorders display a known immune-escape mechanism, we show that lenalidomide can overcome the immunosuppressive impact of(More)
  • 1